- Home
- CRMT vs CTNM Comparison
CRMT vs CTNM Comparison
Compare CRMT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMT
- CTNM
- Stock Information
- Founded
- CRMT 1981
- CTNM 2009
- Country
- CRMT United States
- CTNM United States
- Employees
- CRMT N/A
- CTNM N/A
- Industry
- CRMT Other Specialty Stores
- CTNM
- Sector
- CRMT Consumer Discretionary
- CTNM
- Exchange
- CRMT Nasdaq
- CTNM Nasdaq
- Market Cap
- CRMT 266.5M
- CTNM 248.7M
- IPO Year
- CRMT N/A
- CTNM 2024
- Fundamental
- Price
- CRMT $27.04
- CTNM $11.21
- Analyst Decision
- CRMT Buy
- CTNM Strong Buy
- Analyst Count
- CRMT 1
- CTNM 5
- Target Price
- CRMT $45.00
- CTNM $22.20
- AVG Volume (30 Days)
- CRMT 188.3K
- CTNM 201.6K
- Earning Date
- CRMT 09-04-2025
- CTNM 11-05-2025
- Dividend Yield
- CRMT N/A
- CTNM N/A
- EPS Growth
- CRMT N/A
- CTNM N/A
- EPS
- CRMT 1.61
- CTNM N/A
- Revenue
- CRMT $1,378,681,000.00
- CTNM N/A
- Revenue This Year
- CRMT $6.23
- CTNM N/A
- Revenue Next Year
- CRMT $5.10
- CTNM N/A
- P/E Ratio
- CRMT $16.74
- CTNM N/A
- Revenue Growth
- CRMT 0.64
- CTNM N/A
- 52 Week Low
- CRMT $26.47
- CTNM $3.35
- 52 Week High
- CRMT $62.72
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- CRMT 26.96
- CTNM 55.51
- Support Level
- CRMT $28.33
- CTNM $10.65
- Resistance Level
- CRMT $30.75
- CTNM $12.14
- Average True Range (ATR)
- CRMT 1.53
- CTNM 0.97
- MACD
- CRMT 0.06
- CTNM -0.23
- Stochastic Oscillator
- CRMT 7.63
- CTNM 32.20
About CRMT America's Car-Mart Inc
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.